Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

Abstract

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30. It is highly effective for relapsed/refractory classical Hodgkin lymphoma (CHL), and has become a promising treatment option for these patients; however, approximately 25 % of patients are refractory to BV. Until now, the clinicopathologic features of CHL refractory to BV have not been well understood. Here, we report a patient with relapsed CHL with an unfavorable outcome, whose disease was primary refractory to BV and was histologically diagnosed as a transformation from mixed cellularity CHL to CD30-positive diffuse large B-cell lymphoma (DLBCL). The transformation to DLBCL showing high tumor density and high proliferative activity (Ki67 index >90 %) was possibly related to the primary refractory to BV and an aggressive clinical course, although the lymphoma was diffusely and strongly positive for CD30.

• Authors: Shinichi Makita, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Hideaki Kitahara, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Yukio Kobayashi, Kensei Tobinai
• Journal: International journal of hematology (Int J Hematol) Vol. 104 Issue 3 Pg. 396-9 (Sep 2016) ISSN: 1865-3774 [Electronic] Japan
• PMID: 27169615 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoconjugates
• Ki-1 Antigen
• Brentuximab Vedotin

Topics

• Brentuximab Vedotin
• Cell Transformation, Neoplastic (pathology)
• Drug Resistance, Neoplasm
• Hodgkin Disease (drug therapy, pathology)
• Humans
• Immunoconjugates (therapeutic use)
• Ki-1 Antigen
• Lymphoma, Large B-Cell, Diffuse (pathology)